Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder

Novartis

Status and phase: Completed; Phase 2

Conditions: Anxiety Disorders

Treatments: Drug: XBD173

Study type: Interventional

Funder types: Industry

Identifiers

NCT00108836

CXBD173A2204

Details and patient eligibility

About

This study will test the efficacy, safety and tolerability of XBD173 in the treatment of generalized anxiety disorder in patients.

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Current doctor's diagnosis of generalized anxiety disorder
• In need of psychiatric treatment
• Willingness to complete all aspects of the study

Exclusion criteria

• Current doctor's diagnosis of major depression
• History of schizophrenia or schizoaffective disorders
• Drug dependence within 2 months prior to study start

For detailed information on eligibility, please contact the study center nearest to you (see below), or call 1-862-778-8300, or visit the following website:

www.novartisclinicaltrials.com

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind